Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D Receptor Partners and Regulatory Networks: Full Evidence Review

Previous related pageVitamin D Receptor Partners and Regulatory Networks: Study SummaryNext related pageVitamin D Receptor Partners and Regulatory Networks: Study Summary
Study at a glance

What question did the studies ask?

Researchers asked which proteins work with the vitamin D receptor and how strong the evidence is. The receptor is a protein that responds to active vitamin D. Studies used human and rat cell models, isolated protein parts and mice. Some cell models came from cancers. These were not clinical treatment trials.

What did the researchers find?

Some experiments found direct binding between isolated protein parts. Others found proteins together in cell extracts or at related DNA regions. DNA carries genetic information. Finding proteins at the same DNA region does not prove that they directly bind each other.

Changing a gene or protein supported particular changes in gene activity. Many proposed connections between gene-regulating proteins were not fully tested. A mouse blood-vessel study used toxic injected vitamin D3 doses and produced harmful mineral deposits. It does not predict ordinary supplement effects. In another mouse experiment, a receptor unable to bind hormone normally still preserved selected hair-cycle functions. Receptor loss is different from low vitamin D supply.

What does this mean?

Some experiments used calcitriol, the active vitamin D hormone. Others used a laboratory-made receptor activator with a separate substance limiting another protein’s action. These exposures differ from oral vitamin D3. The studies support specific partnerships with important limits. They do not establish that the same set of proteins always improves function or that every tissue effect comes from one contact between two proteins. They do not provide a personal treatment dose.

Read the full article below ↓

Vitamin D receptor partners are supported by several kinds of evidence: predicted regulatory networks, proteins occupying related DNA regions, proteins recovered together from cells, purified-protein binding and functional perturbation. These are not equivalent demonstrations of one physical complex or one physiological mechanism. This review compares what the experiments establish about cooperation, repression and context-dependent gene regulation. For the shorter account, read Vitamin D Receptor Partners and Regulatory Networks: Study Summary.

What would establish a regulatory partnership?

Transcription factors and their associated proteins influence gene activity. A predicted binding motif is a candidate DNA sequence, not proof that a protein occupied it. Occupancy measurements can show where proteins were associated with DNA; recovery of two proteins together can show association within a complex. Purified-protein experiments can test direct biochemical interaction. Perturbation asks whether changing a component alters the response. The broader question is introduced in Vitamin D and Transcription Factors.

Each method answers part of the question. A co-precipitated protein can be connected indirectly through other proteins. A purified domain can bind outside its normal cellular setting. A knockout can alter many functions at once. The strongest claim that a particular interface causes an outcome requires more than these observations considered separately. This focused primary-study comparison therefore weighs the tested mechanism and remaining alternatives, rather than counting partner names as established causal connections.

The vitamin D receptor, abbreviated VDR, belongs to the family discussed in Vitamin D and Nuclear Receptors. Receptor presence, hormone binding and interaction with another regulator can have different consequences. Vitamin D Receptors provides the receptor background. Most experiments below use calcitriol, the active vitamin D hormone, a synthetic ligand or receptor mutations; none should be treated as interchangeable with ordinary oral vitamin D3.

A transcription-factor network: prediction and selected tests

Warwick and colleagues analysed calcitriol-responsive transcription in human THP-1 monocytic leukaemia cells, including a VDR-knockout comparison. The network model predicted 47 primary transcription-factor targets and later responses. Selected CEBPA and ETS1 binding was examined, but selective factor depletion was performed for CEBPA, not both factors. This distinguishes evidence that a protein was bound from evidence that reducing it changed a response. [1]

Among 1,256 predicted CEBPA-bound genes, 734 responded in control cells, depleted cells or both: 124 lost a detected response, 162 gained one and 448 retained one. Some retained responses changed in magnitude. The result is not that every predicted target was abolished by depletion, or that all 47 predicted factors were experimentally validated. Regulatory networks can produce gains as well as losses when one component is reduced. [1]

The transcriptomic knockout comparison used one edited clone and one control clone, even though several guide lines had protein-level validation. Older binding, accessibility and perturbation datasets were reused within the analysis. These are useful integrated measurements, not wholly independent experiments every time they appear in a new network diagram. The transition from regulator prediction to actual RNA output is part of Vitamin D and Gene Expression. [1]

Purified interaction and nonclassical transcriptional repression

Ito and colleagues examined VDR regulation of SMAD3, a transcriptional regulator involved in fibrosis-associated responses. Purified receptor ligand-binding and SMAD3 DNA-binding domains interacted. The experiments supported interference with SMAD3 DNA binding, and VDR variants unable to bind ordinary vitamin D response elements still repressed a SMAD-dependent reporter. This is stronger direct biochemical interaction evidence than co-occupancy or motif prediction alone. [2]

The regulatory consequence was altered SMAD-dependent transcription. Nonclassical here does not mean rapid nontranscriptional signalling or an absence of gene regulation. Selected fibrogenic transcripts decreased without an equivalent reduction in the upstream TGF-beta transcript or SMAD3 phosphorylation. Mouse renal-injury results supplied a tissue context, but did not establish ordinary vitamin D3 clinical efficacy or long-term safety of the experimental ligands. [2]

Liver genomic cooperation is a distinct mechanism

Ding and colleagues studied hepatic stellate cells, including primary rat and mouse cells and a human stellate-cell line. TGF-beta altered the receptor binding landscape. Selected VDR and SMAD3 regions showed related occupancy, with sequential binding and time-course tests going beyond a predicted shared motif. Ligand-associated receptor recruitment was followed by reduced SMAD3 occupancy at selected loci. [3]

VDR depletion reversed the tested occupancy reduction and repression; SMAD depletion reduced inducible VDR binding. These perturbations strengthen a context-dependent genomic antagonism model. They do not show that VDR and SMAD3 directly bind as purified proteins in this liver experiment, or that every nearby assigned gene is causally controlled by every peak. The liver result and the renal purified-domain result should remain separate mechanisms rather than being collapsed into one universal interaction. [3] [2]

Calcipotriol, a synthetic receptor ligand, modified fibrosis-associated structure in an injured-mouse model. That does not establish human liver function or isolate a particular physical interface as the in-vivo mediator. Main-paper occupancy evidence also does not itself establish every proposed histone or cofactor modification. Vitamin D and Epigenetic Regulation explains why protein binding and chromatin marks are different measurements. [3]

Chromatin-remodelling complexes: an experimentally tested exchange

Wei and colleagues combined biochemical systems, rat INS1 insulin-secreting cells under cytokine stress and mouse diabetes models. Acetylation at receptor lysine 91 supported interaction with BRD9 or BRD7, proteins associated with alternative chromatin-remodelling complexes. Ligand treatment reduced VDR: BRD9 association and increased VDR: BRD7 association. A BRD9 inhibitor helped shift the balance towards PBAF rather than BAF. [4]

Purified BRD9-domain binding, receptor binding mutants and acetylation-enzyme experiments support the proposed recognition mechanism. Reducing PBRM1, a PBAF component, or PCAF, an acetylation-related enzyme, attenuated selected Nfkbia transcriptional responses. Accessibility and histone-acetylation experiments showed locus: and context-dependent changes rather than universal opening. These measurements provide more than an association between a protein name and a pathway label. [4]

The mouse experiments combined calcipotriol with the BRD9 inhibitor. Selected glucose, insulin and islet outcomes improved partially and differently across models. Single agents had limited benefit in some severe settings. The data do not isolate the proposed interface as the sole cause of whole-animal benefit; other-tissue and off-target effects remain possible. Prolonged gene expression during continuing treatment also does not establish memory after withdrawal. Human islet experiments were not trials in people receiving treatment and do not establish clinical efficacy or long-term safety. [4]

RXR-gamma and oligodendrocyte maturation

De la Fuente and colleagues studied neonatal rat oligodendrocyte progenitors, cells already within the lineage that makes myelin around nerve fibres. They reported RXR-gamma/VDR association alongside receptor antagonism, gene silencing and maturation measurements. RXR-gamma is another nuclear receptor. The findings support cooperation in that context, but do not selectively disrupt and rescue only the proposed heterodimer interface. [5]

The ligand response depended on the culture environment: extra calcitriol did not add a differentiation response in ordinary-serum conditions, whereas a response appeared after charcoal treatment of earlier culture serum. Charcoal removes other steroids as well, so this is not a perfectly isolated vitamin D depletion experiment. Receptor dependence cannot be converted into a universal benefit from more ligand. Vitamin D and Cell Differentiation explains the difference between maturation and a newly chosen lineage. [5]

Tissue-slice myelin-associated endpoints extended the evidence beyond a protein marker, but did not measure electrical conduction, behaviour or human repair. The connection to Vitamin D and Regeneration therefore remains specific to measured organisation, not an established clinical regenerative effect or proof that the receptor-pair interface alone mediated it. [5]

RUNX2 cooperation in a pathological vascular programme

Han and colleagues connected VDR and RUNX2, a regulator associated with bone-cell programmes, in vascular smooth-muscle experiments. Co-immunoprecipitation used transfected HEK293 cells, not purified proteins or an isolated native vascular interface. Genetic and culture perturbations strengthened a functional cooperation argument, but the association assay alone did not establish direct binding in a normal blood vessel. [6]

The animal phenotype involved toxic injected vitamin D3 exposures and vascular mineralisation. Global receptor loss changes systemic mineral regulation; RUNX2-mutant protection despite raised calcium supports a contribution beyond calcium alone without excluding every systemic alternative. This is an important counterweight to equating regulatory cooperation with beneficial maturation. The programme did not test ordinary supplement use, blood flow or cardiovascular events. [6]

A regulatory DNA variant is not another protein-partner proof

Witonsky and colleagues examined a POLB-associated insertion/deletion in human donor-derived colon organoids. Reporter constructs and VDR binding tests supported a regulatory region more strongly than a predicted response-element motif alone. Binding evidence at the present region must be distinguished from a genotype where the region itself is absent. This is a DNA-regulatory-context experiment, not proof that POLB is a physical transcription-factor partner. [7]

There was no selective endogenous edit establishing that the candidate sequence explained every genotype-associated response. Six-hour RNA and later selected protein findings also did not measure actual DNA-repair performance or cancer prevention. Broad ancestry-group responses were similar overall, while precise donor accounting remains inconsistent across paper sections and supporting tables. The genotype-centred result should stay bounded to its tested assays and populations. [7]

A receptor function can remain without conventional ligand binding

Skorija and colleagues expressed human receptor variants in the skin of Vdr-null mice. A ligand-binding-defective variant restored selected early and longer-term hair-cycle outcomes despite lacking conventional hormone binding and ligand-dependent reporter activation. A different receptor variant gave less complete long-term rescue. The experiments show that receptor presence cannot always be replaced conceptually by ligand availability. [8]

Both variants retained association with Hairless and repression-related activity in cellular assays, but no selective Hairless-interface experiment established that partnership as the sole cause of rescue. Small transgenic groups and expression differences constrain generalisation. The result does not show that all skin functions are ligand-independent or that extra vitamin D repairs receptor loss. It also illustrates the wider distinction in Vitamin D Status vs Vitamin D Effect: measured supply is not a complete description of receptor function. [8]

From receptor partners to gene responses

The studies support several routes: direct interference with another factor’s DNA binding, stimulus-dependent genomic occupancy, chromatin-complex exchange and context-dependent cooperation during maturation or pathological mineralisation. Each claim needs its tested level of evidence. A receptor knockout can support dependence without identifying a particular partner interface; a binding assay can support association without proving that interface causes the tissue outcome. [2] [3] [4] [5] [6]

The network and POLB studies similarly distinguish predictions, DNA occupancy, reporter activity, RNA and protein. Selective perturbation can strengthen causal attribution while leaving other components or compensatory pathways active. These findings explain regulatory organisation; they do not establish one universally beneficial network or demonstrate that an oral vitamin D3 regimen reproduces every laboratory response. [1] [7]

Evidence typeActual exampleClaim still requiring more evidence
Predicted network and selected depletionCEBPA-dependent changes within a larger proposed hierarchyAll predicted factors or every edge are causal
Purified-domain interactionVDR: SMAD3 binding and DNA-binding interferenceOne interface explains all tissue responses
Genomic occupancy plus perturbationStimulus-dependent liver VDR/SMAD3 patternsUniversal direct protein binding or every nearest gene is causal
Cofactor exchange and chromatin testsBRD9/BRD7-associated BAF/PBAF changesSelective interface causation of all mouse metabolic outcomes
Association and maturation/pathologyRXR-gamma or RUNX2-related experimentsOrdinary supplementation benefits or isolated partner mediation
Regulatory DNA reporter and receptor bindingPOLB-associated variant regionEndogenous sequence causality and DNA-repair benefit

The strongest conclusion is a graded one. Several partnerships have substantial biochemical and functional support, while many network links remain predicted and some physiological mechanisms are incompletely isolated. Ligand, receptor, partner, DNA context and cell state all matter. Keeping those evidence levels separate preserves what the experiments establish without converting a plausible regulatory model into a demonstrated treatment mechanism.

Scientific sources

[1] A hierarchical regulatory network analysis of the vitamin D induced transcriptome reveals novel regulators and complete VDR dependency in monocytes. Warwick T, Schulz MH, Günther S, Gilsbach R, Neme A, Carlberg C, Brandes RP, Seuter S. Scientific reports. 2021;11(1):6518. DOI 10.1038/s41598-021-86032-5; PMID 33753848; PMCID PMC7985518.

[2] A nonclassical vitamin D receptor pathway suppresses renal fibrosis. Ito I, Waku T, Aoki M, Abe R, Nagai Y, Watanabe T, Nakajima Y, Ohkido I, Yokoyama K, Miyachi H, Shimizu T, Murayama A, Kishimoto H, Nagasawa K, Yanagisawa J. The Journal of clinical investigation. 2013;123(11):4579-4594. DOI 10.1172/jci67804; PMID 24135137; PMCID PMC3809783.

[3] A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. Cell. 2013;153(3):601-613. DOI 10.1016/j.cell.2013.03.028; PMID 23622244; PMCID PMC3673534.

[4] Vitamin D Switches BAF Complexes to Protect β Cells. Wei Z, Yoshihara E, He N, Hah N, Fan W, Pinto AFM, Huddy T, Wang Y, Ross B, Estepa G, Dai Y, Ding N, Sherman MH, Fang S, Zhao X, Liddle C, Atkins AR, Yu RT, Downes M, Evans RM. Cell. 2018;173(5):1135-1149.e15. DOI 10.1016/j.cell.2018.04.013; PMID 29754817; PMCID PMC5987229.

[5] Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. de la Fuente AG, Errea O, van Wijngaarden P, Gonzalez GA, Kerninon C, Jarjour AA, Lewis HJ, Jones CA, Nait-Oumesmar B, Zhao C, Huang JK, ffrench-Constant C, Franklin RJ. The Journal of cell biology. 2015;211(5):975-985. DOI 10.1083/jcb.201505119; PMID 26644513; PMCID PMC4674280.

[6] Functional cooperation between vitamin D receptor and Runx2 in vitamin D-induced vascular calcification. Han MS, Che X, Cho GH, Park HR, Lim KE, Park NR, Jin JS, Jung YK, Jeong JH, Lee IK, Kato S, Choi JY. PloS one. 2013;8(12):e83584. DOI 10.1371/journal.pone.0083584; PMID 24349534; PMCID PMC3861528.

[7] Genomic profiling of active vitamin D colonic responses in African: and European-Americans identifies an ancestry-related regulatory variant of POLB. Witonsky D, Laxman B, Usman H, Bielski MC, Lawrence KM, Kupfer SS. PLoS genetics. 2026;22(1):e1011983. DOI 10.1371/journal.pgen.1011983; PMID 41505470; PMCID PMC12810902.

[8] Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, Demay MB. Molecular endocrinology (Baltimore, Md.). 2005;19(4):855-862. DOI 10.1210/me.2004-0415; PMID 15591533.

Related reading

Original sources

Source

A hierarchical regulatory network analysis of the vitamin D induced transcriptome reveals novel regulators and complete VDR dependency in monocytes

The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3).

Publication details

[1] A hierarchical regulatory network analysis of the vitamin D induced transcriptome reveals novel regulators and complete VDR dependency in monocytes. Warwick T, Schulz MH, Günther S, Gilsbach R, Neme A, Carlberg C, Brandes RP, Seuter S. Scientific reports. 2021;11(1):6518. DOI 10.1038/s41598-021-86032-5; PMID 33753848; PMCID PMC7985518.

Read more →
Source

A nonclassical vitamin D receptor pathway suppresses renal fibrosis.

[2] A nonclassical vitamin D receptor pathway suppresses renal fibrosis.

Publication details

[2] A nonclassical vitamin D receptor pathway suppresses renal fibrosis. Ito I, Waku T, Aoki M, Abe R, Nagai Y, Watanabe T, Nakajima Y, Ohkido I, Yokoyama K, Miyachi H, Shimizu T, Murayama A, Kishimoto H, Nagasawa K, Yanagisawa J. The Journal of clinical investigation. 2013;123(11):4579-4594. DOI 10.1172/jci67804; PMID 24135137; PMCID PMC3809783.

Read more →
Source

A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response.

[3] A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response.

Publication details

[3] A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. Cell. 2013;153(3):601-613. DOI 10.1016/j.cell.2013.03.028; PMID 23622244; PMCID PMC3673534.

Read more →
Source

Vitamin D Switches BAF Complexes to Protect β Cells.

[4] Vitamin D Switches BAF Complexes to Protect β Cells.

Publication details

[4] Vitamin D Switches BAF Complexes to Protect β Cells. Wei Z, Yoshihara E, He N, Hah N, Fan W, Pinto AFM, Huddy T, Wang Y, Ross B, Estepa G, Dai Y, Ding N, Sherman MH, Fang S, Zhao X, Liddle C, Atkins AR, Yu RT, Downes M, Evans RM. Cell. 2018;173(5):1135-1149.e15. DOI 10.1016/j.cell.2018.04.013; PMID 29754817; PMCID PMC5987229.

Read more →
Source

Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.

[5] Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.

Publication details

[5] Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. de la Fuente AG, Errea O, van Wijngaarden P, Gonzalez GA, Kerninon C, Jarjour AA, Lewis HJ, Jones CA, Nait-Oumesmar B, Zhao C, Huang JK, ffrench-Constant C, Franklin RJ. The Journal of cell biology. 2015;211(5):975-985. DOI 10.1083/jcb.201505119; PMID 26644513; PMCID PMC4674280.

Read more →
Source

Functional Cooperation between Vitamin D Receptor and Runx2 in Vitamin D-Induced Vascular Calcification

The transdifferentiation of vascular smooth muscle cells (VSMCs) into osteoblast-like cells has been implicated in the context of vascular calcification.

Publication details

[6] Functional cooperation between vitamin D receptor and Runx2 in vitamin D-induced vascular calcification. Han MS, Che X, Cho GH, Park HR, Lim KE, Park NR, Jin JS, Jung YK, Jeong JH, Lee IK, Kato S, Choi JY. PloS one. 2013;8(12):e83584. DOI 10.1371/journal.pone.0083584; PMID 24349534; PMCID PMC3861528.

Read more →
Source

Genomic profiling of active vitamin D colonic responses in African- and European-Americans identifies an ancestry-related regulatory variant of POLB

In our study, we aimed to understand how active vitamin D affects colon cells from people with African and European backgrounds.

Publication details

[7] Genomic profiling of active vitamin D colonic responses in African: and European-Americans identifies an ancestry-related regulatory variant of POLB. Witonsky D, Laxman B, Usman H, Bielski MC, Lawrence KM, Kupfer SS. PLoS genetics. 2026;22(1):e1011983. DOI 10.1371/journal.pgen.1011983; PMID 41505470; PMCID PMC12810902.

Read more →
Source

Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis.

Published in Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, Demay MB. Molecular endocrinology (Baltimore, Md.) (2005).

Publication details

[8] Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, Demay MB. Molecular endocrinology (Baltimore, Md.). 2005;19(4):855-862. DOI 10.1210/me.2004-0415; PMID 15591533.

Read more →